🔥 Bitget US Stock Hotspot Sniper｜2026.08.20 Main Theme: mRNA Cancer Breakthrough｜AI Chip Partnership · Treasury Buyback · Memory Buyback

1. Moderna/Merck Personalized mRNA Cancer Vaccine Phase 3 Success The personalized mRNA vaccine (intismeran) combined with Keytruda met primary endpoints in a late-stage trial of over 1,100 high-risk melanoma patients, significantly extending recurrence-free survival and distant metastasis-free survival. This marks the first successful Phase 3 result for a personalized mRNA cancer therapy. 🎯 Beneficiaries: MRNA, MRK; Key catalyst: mRNA technology shifts from prevention to oncology validation; watch follow-on data in other solid tumors and commercialization progress.
2. Marvell Secures Major Google Custom AI Chip Partnership Marvell expanded its collaboration with Google covering custom silicon for the TPU ecosystem, including AI inference accelerators, storage controllers, network interface controllers, and near-memory compute. Google received warrants for up to approximately 58.97 million shares at $206.58 exercise price (potential value ~$12.2 billion). 🎯 Beneficiaries: MRVL, GOOGL; Key catalyst: AI supply-chain diversification accelerates; MRVL challenges Broadcom narrative continues to develop.
3. US Treasury Doubles Long-Term Bond Buyback Size The Treasury will at least double the size of liquidity-support buybacks for 10- to 30-year nominal Treasuries to a minimum of $4 billion per operation (effective from September 9). Long-term yields fell sharply (30-year to around 5.18%), easing valuation pressure. 🎯 Beneficiaries: SPY, QQQ, growth stocks broadly; Key catalyst: Temporary relief in bond-market pressure helped major indexes end a three-day slide.
4. SK Hynix Launches 40 Trillion Won Share Buyback & Cancellation SK Hynix will repurchase and cancel approximately 24.07 million shares worth 40 trillion won (~$28.6 billion), starting August 20 for about three months. The company also raised its 2025–2027 shareholder-return target to more than 50% of cumulative free cash flow. 🎯 Beneficiaries: SKHY, MU, SNDK; Key catalyst: AI-driven memory cash-flow strength confirmed; valuation-repair window opens.
5. Target Q2 Earnings Beat Expectations Target reported Q2 sales up 5.3% and comparable sales up 3.8%, with growth across most segments, exceeding market expectations and supporting retail sentiment. 🎯 Beneficiaries: TGT, related retail names; Key catalyst: Consumer resilience verified; watch subsequent retail earnings and spending data.

Trading note: Biotech event momentum is strong, AI chip supply-chain rotation is clear (MRVL strength vs. pressure in parts of memory/optical), and Treasury buybacks provide short-term valuation support. Monitor volume and today’s WMT earnings window for positioning. US stocks have seen elevated volatility recently. The above is for informational reference only and does not constitute investment advice.